January 24, 2013
After gaining FDA approval for its chronic myeloid leukemia drug Iclusig in December, all eyes have been on Ariad Pharmaceuticals' (NASDAQ: ARIA ) launch of the product. This drug is entering a competitive market currently dominated by big pharma companies Novartis and Bristol-Myers Squibb.
With commercial activities ramping up, clinical trials ongoing, and preparations under way to potentially launch Iclusig in Europe, the company is in need of more capital. In this video, health-care analyst Max Macaluso discusses why Ariad's announcement of an upcoming $300 million public offering is an essential long-term move for the company.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.